Chemistry:Sovateltide
From HandWiki
Short description: Chemical compound
Clinical data | |
---|---|
Trade names | Tyvalzi |
Other names | IRL-1620; PMZ-1620 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
ChEMBL | |
Chemical and physical data | |
Formula | C86H117N17O27 |
Molar mass | 1820.974 g·mol−1 |
3D model (JSmol) | |
| |
|
Sovateltide (development names IRL-1620 and PMZ-1620,[1] sold under the brand name Tyvalzi)[2] is a synthetic analog of endothelin-1 that works as a selective endothelin-B receptor agonist. In May 2023, it was approved in India to treat acute ischemic stroke. The drug was developed by Pharmazz.[2]
References
- ↑ Gulati, Anil; Agrawal, Nilesh; Vibha, Deepti; Misra, U. K.; Paul, Birinder; Jain, Dinesh; Pandian, Jeyaraj; Borgohain, Rupam (January 2021). "Safety and Efficacy of Sovateltide (IRL-1620) in a Multicenter Randomized Controlled Clinical Trial in Patients with Acute Cerebral Ischemic Stroke". CNS Drugs 35 (1): 85–104. doi:10.1007/s40263-020-00783-9. ISSN 1179-1934. PMID 33428177.
- ↑ 2.0 2.1 Keam, Susan J. (September 2023). "Sovateltide: First Approval". Drugs 83 (13): 1239–1244. doi:10.1007/s40265-023-01922-4. ISSN 1179-1950. PMID 37486545. https://pubmed.ncbi.nlm.nih.gov/37486545/.
Original source: https://en.wikipedia.org/wiki/Sovateltide.
Read more |